BiomeBank
Australian biotech leveraging co‑cultured gut microbiome consortia to deliver regulated, scalable therapies for C. and and ulcerative colitis.
Private Company
Estimated funding: $10M
AI Company Overview
Australian biotech leveraging co‑cultured gut microbiome consortia to deliver regulated, scalable therapies for C. and and ulcerative colitis.
Technology Platform
CONSORTIOME® is a proprietary co‑culturing platform that assembles complex, defined microbial consortia replicating >90% of the gene families of a healthy human gut, enabling scalable, reproducible microbiome therapeutics.
Opportunities
Risk Factors
Competitive Landscape
Key competitors include Seres Therapeutics, Finch Therapeutics, and Rebiotix; BiomeBank differentiates itself through co‑cultured consortia that offer greater functional diversity and manufacturing consistency than single‑strain or donor‑derived products.